Anti-PTGFR antibodies are immunoglobulins that specifically recognize and bind PTGFR, the gene encoding the prostaglandin F2-alpha receptor in humans. In research applications, these antibodies are used to detect PTGFR in tissue samples, cell lysates, and cultured cells. PTGFR is a G protein-coupled receptor for prostaglandin F2-alpha that signals through a phosphatidylinositol-calcium second messenger system and initiates luteolysis in the corpus luteum. Because prostaglandin F2-alpha signaling through PTGFR drives uterine contraction and luteal regression, this receptor is widely studied in reproductive and parturition research.
Catalog highlights and purchasing considerations
About the Biocompare PTGFR antibody catalog
The Biocompare antibody search tool lists PTGFR antibodies from a wide range of suppliers, with western blot, immunohistochemistry, and immunofluorescence among the most common validated applications. Listings may also appear under the gene symbol PTGFR or the common abbreviation FP receptor. Several PTGFR antibodies mentioned here have been cited across a range of reproductive biology research, including studies on AOC1-regulated labor initiation through spermidine-induced trophoblast autophagy, reproductive tract microbiota dysbiosis in endometrioma and adenomyosis, and the role of PGF2-alpha in canine periparturient myometrium.
Considerations when choosing a PTGFR antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.